Navigation Links
Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
Date:2/13/2008

Review of VistaCare's first quarter operating results further convinces

Accipiter that Odyssey is acquiring VistaCare at a discount

NEW YORK, Feb. 13 /PRNewswire/ -- Accipiter Capital Management, the owner, together with its affiliates, of nearly 10% of the outstanding shares of common stock of VistaCare, Inc. (Nasdaq: VSTA), announced today that it had delivered a letter to VistaCare's Board of Directors stating that a review of VistaCare's Quarterly Report for the quarterly period ended December 31, 2007, has further convinced Accipiter that the offer by Odyssey Healthcare, Inc. (Nasdaq: ODSY) to acquire VistaCare for $8.60 per share is wholly inadequate. The letter further indicated that Accipiter was troubled by inconsistencies between VistaCare's internal analysis of the Company's restructuring and information VistaCare's management disclosed to investors. The letter calls on VistaCare's Board of Directors to explain these inconsistencies to stockholders and urges stockholders not to tender their shares in connection with the acquisition and to exercise their appraisal rights to the full extent permissible under law should the tender offer and subsequent merger be consummated.

Accipiter Capital Management and its affiliates do not intend to tender their shares in connection with the acquisition and plan to exercise their appraisal rights to the full extent permissible under law should the tender offer and subsequent merger be consummated. The text of the letter from Accipiter Capital Management to the Board of Directors of VistaCare follows:

ACCIPITER CAPITAL MANAGEMENT

February 13, 2008

BY FACSIMILE AND FEDERAL EXPRESS

The Board of Directors

VistaCare, Inc.

4800 North Scottsdale Road

Suite 5000

Scottsdale, AZ 85251

Ladies and Gentlemen:

Accipiter Capital Management and its affiliates (collectively "Accipiter" or "we") have reviewed the Quarterly Report for the quarterly period ended December 31, 2007 (the "10-Q"), filed by VistaCare, Inc. ("VistaCare" or the "Company") on February 8, 2008. Careful review of VistaCare's results for its first fiscal quarter (the "First Quarter") as disclosed in the 10-Q has reinforced our belief that the offer by Odyssey Healthcare, Inc., through Odyssey Investment, Inc., a wholly owned subsidiary of Odyssey HealthCare Holding Company (collectively, "Odyssey") to acquire the Company for $8.60 per share (the "Acquisition") is a discount bid rather than a premium.

It is clear to us from the 10-Q that VistaCare significantly outperformed analyst expectations for the First Quarter -- reporting EBITDA of $2.2 million and earnings per share of $0.09 versus analysts' estimates of $1.6 million of EBITDA and earnings per share of $0.05. If VistaCare were to remain independent, we believe the Company's future results would be even higher considering VistaCare's corporate restructuring activities (the "Restructuring") occurred throughout the quarter and the full benefits are not yet fully reflected Company's operating results. Although VistaCare publicly disclosed in its Solicitation/Recommendation Statement filed on January 30, 2008 (the "Recommendation") that the Restructuring has fallen behind internal expectations, independent analyst estimates signal, and the results disclosed in the 10-Q confirm, that the Restructuring is well ahead of Wall Street's expectations. Furthermore, the 10-Q signifies strong cash flow, as indicated by the increase in the cash net of VistaCare's Medicare cap liability from $18 million on September 30, 2007 to $23 million on December 31, 2007. Based on these results we believe VistaCare is effectively being purchased for $7.20 per share in enterprise value, $0.30 lower than our previous estimate. In fact, these results have further convinced us that had VistaCare not agreed to a takeover, the Company's stock price would currently be well ahead of the $8.60 per share purchase price being offered by Odyssey.

Although we are pleased with VistaCare's restructuring success so far, we are also troubled by the Company's disclosure in the 10-Q relating to inconsistencies between management's internal analysis of the Restructuring's progress versus the information the Company's management disclosed to investors. For example, as first publicly disclosed in the Recommendation, on November 14, 2007, management noted to the Board that the estimated benefits of the Restructuring would not be realized as soon as initially projected and, therefore, fiscal 2008 projected financial targets may be lower than forecasted. However, management made no mention of this on their quarterly conference call, held on December 11, 2007. In fact, on that particular call Rick Slager, VistaCare's Chief Executive Officer, spoke positively about the Company's turnaround progress, stating, "[w]e made substantial progress towards achieving the goals of our restructuring plan during this fiscal fourth quarter." Additionally, when Henry Hirvela, VistaCare's Chief Financial Officer, was asked about the Company's goal of 10% EBITDA for the fourth quarter of fiscal 2008, he responded, "I think that is pretty much the guidance that we are going to be staying with as we go forward." We call on the Board to explain these inconsistencies to investors.

We are also troubled by other recent actions taken by management. In particular,

-- We note that VistaCare waited to disclose that the Company was behind

on the Restructuring until January 30, 2008, more than two months

after disclosing this to the Board.

-- We note that VistaCare failed to hold a conference call to discuss

the Acquisition or to discuss the December Quarter results.

-- We note that if the merger is consummated and management is not

retained, VistaCare's CEO will receive severance payments of

approximately $1.73 million, three times his then current salary,

plus benefits for three years, upon termination after a change of

control, in spite of the fact that, up to this point, the Company's

profitability severely lags relative to its peers.

As this is a strategic acquisition, we anticipate Odyssey will seek to achieve cost savings by reducing redundant management. So who stands to gain the most if Odyssey acquires VistaCare -- VistaCare's stockholders or its management who will be handsomely rewarded if terminated?

We believe that VistaCare would be significantly more valuable as a standalone company with new management more capable of effectuating a timely turnaround. Consequently, we strongly urge stockholders not to tender their shares to Odyssey and to exercise their appraisal rights in accordance with Section 262 of the Delaware General Corporation Law should the tender offer and subsequent merger be consummated.

Sincerely,

Gabe Hoffman Nicole Viglucci


'/>"/>
SOURCE Accipiter Capital Management
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rural/Metro Board of Directors Meets With Accipiter Capital Management
2. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. AtriCure to Present at Roth Capital Partners 2007 New York Conference
5. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
6. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
7. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
8. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
9. Pharsight Files Application for Nasdaq Capital Market Listing
10. Advanced Life Sciences Joins NASDAQ Capital Market
11. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone Factor ... to empower WeightZone Factor members to track their exercise patterns, monitor behavioral changes, ... education, all on their mobile phones. It also provides social networks for members ...
(Date:5/21/2017)... ID (PRWEB) , ... May 20, 2017 , ... ... financial integration systems between ABC Financial Services and financial systems. , ... link or exported files that are electronically processed through GetLinked into their club’s ...
(Date:5/21/2017)... ... May 21, 2017 , ... Florida Pain Relief Group, ... of its newest location at 109 Silver Palm Ave., Melbourne, on Monday, May 22. ... With the opening of the Melbourne practice, PPOA operates 23 pain management clinics in ...
(Date:5/19/2017)... ... May 19, 2017 , ... In a continuous effort to raise ... luxury online mattress company that specializes in natural and organic latex mattresses, has announced ... organization) for every unique share their recent viral Facebook video receives, up ...
(Date:5/19/2017)... Springfield, Vermont (PRWEB) , ... May 19, 2017 , ... ... on its company blog. Titled " Ten Good Reasons To Hire An Experienced Personal ... decisions to make following an accident or injury. As the article says. if someone ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
Breaking Medicine Technology: